康华生物
(300841)
| 流通市值：69.66亿 | | | 总市值：76.74亿 |
| 流通股本：1.22亿 | | | 总股本：1.35亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 1,007,828,965.84 | 1,039,366,021.16 | 750,492,354.64 | 646,792,429.69 |
| 应收票据及应收账款 | 1,361,642,355.65 | 1,410,519,392.7 | 1,317,758,111.78 | 1,324,642,824.04 |
| 应收账款 | 1,361,642,355.65 | 1,410,519,392.7 | 1,317,758,111.78 | 1,324,642,824.04 |
| 预付款项 | 18,910,765.44 | 17,093,688.38 | 22,456,722.28 | 29,575,860.1 |
| 其他应收款合计 | 16,952,135.85 | 16,382,086.18 | 17,525,982.5 | 17,319,790.27 |
| 存货 | 189,113,400.9 | 173,536,297.45 | 184,161,044.06 | 191,194,911.43 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 2,644,447,623.68 | 2,656,897,485.87 | 2,292,394,215.26 | 2,209,525,815.53 |
| 非流动资产: | | | | |
| 长期股权投资 | 6,500,000 | 6,500,000 | - | - |
| 其他非流动金融资产 | 471,392,714.03 | 470,871,012.97 | 519,911,661.67 | 524,411,296.82 |
| 固定资产 | 838,409,092.53 | 849,035,159.71 | 495,754,506.39 | 501,730,334.45 |
| 在建工程 | 111,155,216.74 | 112,254,436.74 | 458,260,265.73 | 467,867,196.9 |
| 使用权资产 | - | - | - | 149,370.37 |
| 无形资产 | 15,372,942.88 | 15,375,932.99 | 16,022,675.98 | 16,244,331.24 |
| 长期待摊费用 | 107,008,337.39 | 94,389,764.96 | 124,965,967.39 | 74,720,218.64 |
| 其他非流动资产 | 7,448,050.86 | 3,944,519 | 7,811,971.4 | 10,937,943.53 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,557,286,354.43 | 1,552,370,826.37 | 1,622,727,048.56 | 1,596,060,691.95 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 4,201,733,978.11 | 4,209,268,312.24 | 3,915,121,263.82 | 3,805,586,507.48 |
| 流动负债: | | | | |
| 短期借款 | 210,191,877.41 | 190,913,849.93 | 125,870,610.61 | 138,862,037.55 |
| 应付票据及应付账款 | 11,269,734.88 | 7,129,147.17 | 35,781,077.81 | 49,894,619.94 |
| 其中：应付票据 | - | 4,000,000 | 24,600,000 | 37,700,369.27 |
| 应付账款 | 11,269,734.88 | 3,129,147.17 | 11,181,077.81 | 12,194,250.67 |
| 合同负债 | 184,511.39 | 295,511.18 | 335,169.09 | 356,059.71 |
| 应付职工薪酬 | 14,370,460.44 | 34,942,933.81 | 25,812,919.15 | 14,349,921.8 |
| 应交税费 | 17,144,179.06 | 42,217,146.97 | 16,365,951.69 | 19,296,169.15 |
| 其他应付款合计 | 335,362,150.06 | 406,217,416.78 | 307,156,757.55 | 300,193,042.74 |
| 一年内到期的非流动负债 | - | - | 1,000,000 | 1,000,000 |
| 其他流动负债 | 5,535.34 | 8,865.34 | 10,055.07 | 5,281.79 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 588,528,448.58 | 681,724,871.18 | 512,332,540.97 | 523,957,132.68 |
| 非流动负债: | | | | |
| 长期借款 | - | - | 15,247,500 | 15,247,500 |
| 预计负债 | 4,024,237.25 | 4,792,273.24 | 3,610,489.88 | 3,216,424.68 |
| 递延收益 | 6,197,177.1 | 6,199,754.1 | 84,492 | - |
| 递延所得税负债 | 1,897,991.22 | 2,499,666.34 | 4,905,737.97 | 4,958,154.97 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 12,119,405.57 | 13,491,693.68 | 23,848,219.85 | 23,422,079.65 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 600,647,854.15 | 695,216,564.86 | 536,180,760.82 | 547,379,212.33 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 134,650,449 | 134,650,449 | 134,650,449 | 134,650,449 |
| 资本公积 | 1,179,543,389.54 | 1,179,543,389.54 | 1,184,710,019.44 | 1,184,710,019.44 |
| 减:库存股 | 185,530,157.25 | 123,097,539.84 | 123,097,539.84 | 123,097,539.84 |
| 盈余公积 | 67,325,224.5 | 67,325,224.5 | 67,325,224.5 | 67,325,224.5 |
| 未分配利润 | 2,405,097,218.17 | 2,255,630,224.18 | 2,115,352,349.9 | 1,994,619,142.05 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 3,601,086,123.96 | 3,514,051,747.38 | 3,378,940,503 | 3,258,207,295.15 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 3,601,086,123.96 | 3,514,051,747.38 | 3,378,940,503 | 3,258,207,295.15 |
| 负债和股东权益合计 | 4,201,733,978.11 | 4,209,268,312.24 | 3,915,121,263.82 | 3,805,586,507.48 |
| 公告日期 | 2024-04-24 | 2024-03-30 | 2023-10-21 | 2023-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |